Ipamorelin

Compound Overview

Ipamorelin is a selective growth hormone secretagogue used in research models to evaluate ghrelin receptor (GHSR-1a) activation and downstream pituitary GH release signaling. In published experimental contexts, Ipamorelin is distinguished from GHS compounds such as GHRP-6 or Hexarelin by its high selectivity for GH release without significant effects on cortisol, prolactin, or ACTH levels in research models.

Research Background & Published Literature

Ipamorelin has a focused literature base as a selective GH secretagogue. Raun et al., published in the European Journal of Endocrinology, characterized the compound's selectivity profile, and the peptide is frequently evaluated with GHRH analogs such as CJC-1295 in combination research designed to study synergistic GH signaling.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Raun et al. (1998) — Eur J Endocrinol
• Venkova et al. (2009) — J Pharmacol Exp Ther
• Andersen et al. (2001) — Growth Horm IGF Res

Storage, Handling & Stability Guidelines

Lyophilized Ipamorelin is highly stable due to its small molecular size (pentapeptide). Store at -20°C. Reconstituted solutions should be kept at 2–8°C and used within 21 days.

• Keep ambient-temperature exposure brief during handling to help preserve compound integrity.
• Reseal vials promptly after each withdrawal to reduce moisture exposure.
• Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
• For traceability, label all aliquots with compound name, concentration, reconstitution date, and operator initials.

Lab Verification

Nexus maintains batch-level verification records for research compounds in the Lab Verified archive, including HPLC purity review and Mass Spectrometry identity confirmation where current lot data is available.